Welcome! This is the NEW free version of the SciBITES Pharma News Engine from SciBite. By using this site you to accept our Terms & Conditions which the use of cookies to enhance your user experience.


Here is the latest news for your query in chronological order, most recent articles at the top. Use the options on the right to filter and customise this news feed.

  Todays Pfizer (Tag) Articles ...

Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies.
Medline, PloS one [12] e0177985, 27-May-2017
A Phase I Open-Label Dose Escalation and Expansion Study of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)
ClinicalTrials.gov, , 27-May-2017
Treatment Patterns And Clinical Outcomes Among Patients Receiving Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings
ClinicalTrials.gov, , 27-May-2017
A Phase 1, Single Center, Randomized, 4-way Crossover, Double Blinded, Placebo And Moxifloxacin Controlled Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects
ClinicalTrials.gov, , 27-May-2017
Illinois Workplace Wellness Study
ClinicalTrials.gov, , 27-May-2017
Pfizer gets FDA panel recommendation for biosimilar EPO
http://www.pmlive.com, , 26-May-2017
Trio of patients sue Pfizer, BMS, claiming they soft-pedaled Eliquis bleeding risks
http://www.fiercepharma.com, , 26-May-2017
FDA panel recommends Pfizer’s epoetin alfa biosimilar to treat anemia
http://regulatoryaffairs.pharmaceutical-business-review.com, , 26-May-2017
FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen® / Procrit® across all indications
http://www.worldpharmanews.com, , 25-May-2017
California Lipitor plaintiffs win a chance to argue the Pfizer medication triggered their diabetes
http://www.fiercepharma.com, , 25-May-2017
FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
http://www.fiercepharma.com, , 25-May-2017
VACCINE FORMULATIONS
US/WO/EU Patents, , 25-May-2017
ANTIBODIES TO M-CSF
US/WO/EU Patents, , 25-May-2017
Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis.
Medline, BMC nephrology [18] 168, 25-May-2017
Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin.
Medline, The AAPS journal, 25-May-2017
A Flow Cytometry-Based Screen Identifies MBNL1 Modulators that Rescue Splicing Defects in Myotonic Dystrophy Type I.
Medline, Human molecular genetics, 25-May-2017
A pipeline combining multiple strategies for prioritizing heterozygous variants for the identification of candidate genes in exome datasets.
Medline, Human genomics [11] 11, 25-May-2017
Pfizer bows first Ibrance TV spot as Novartis revs up with rival breast cancer med Kisqali
http://www.fiercepharma.com, , 24-May-2017
Pfizer's Epogen biosim scores solid backing from FDA staff ahead of panel review
http://www.fiercepharma.com, , 24-May-2017

  This Weeks Pfizer (Tag) Articles ...

Pfizer Vs. Merck: 4 Reasons One Is The Superior Choice
https://seekingalpha.com, , 24-May-2017
Showing Records 0 ... 20  


SciBite
The Language Of Science

SciBite provides text-analytics and data intelligence software for drug discovery, clinical and competitor intelligence and much more for pharma, healthcare and life sciences.

This is a Limited, Free Service only touching the surface of how SciBite's tools transform biomedical text, literature, patents, internal documents and news into a rich intelligence network. If you'd like to know more, contact us to see how our tools can transform your work today!

Topic Activity & Tools

Get Daily Alerts!

Click For Email & RSS Alerts

About/Links

Name: Pfizer (Tag)
Type: Company

Filters

Source:


Must Mention A:


In Context:


Insights

Show Most Frequent


Optional, Only Include Source:


Tools

[Not available (Why?)]